Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and targeted oncology treatments. The company's pipeline includes several candidates in clinical development: Casdatifan, a HIF-2a inhibitor for kidney cancer; Domvanalimab, an anti-TIGIT antibody in Phase 2 and 3 trials for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. The company is also advancing Quemliclustat, a CD73 inhibitor targeting the ATP-adenosine pathway in Phase 3 and Phase 1/1b studies for lung and pancreatic cancer, alongside earlier-stage programs including AB598 (CD39 antibody) and AB801 (AXL inhibitor).

Arcus maintains a clinical collaboration with AstraZeneca to develop domvanalimab in combination with durvalumab for Stage 3 non-small cell lung cancer through the Phase 3 PACIFIC-8 trial. The company also partners with BVF Partners L.P. on inflammatory disease programs. As a clinical-stage company, Arcus generates no significant product revenue and instead relies on collaboration agreements and capital resources to fund operations.

Headquartered in Hayward, California, Arcus operates with approximately 601 full-time employees. The company is incorporated in Delaware and trades on the NYSE.